ObsEva (NASDAQ:OBSV) Raised to Buy at Zacks Investment Research

ObsEva (NASDAQ:OBSVGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm presently has a $1.75 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 4.79% from the stock’s current price.

According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “

OBSV has been the topic of several other reports. Canaccord Genuity Group initiated coverage on ObsEva in a research report on Tuesday, April 26th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of ObsEva in a research report on Monday. StockNews.com raised ObsEva from a “sell” rating to a “hold” rating in a research report on Friday, May 20th. Canaccord Genuity Group initiated coverage on ObsEva in a research report on Tuesday, April 26th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Aegis initiated coverage on ObsEva in a research report on Monday, March 28th. They issued a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ObsEva presently has an average rating of “Buy” and an average target price of $11.63.

Shares of ObsEva stock opened at $1.67 on Thursday. ObsEva has a fifty-two week low of $1.08 and a fifty-two week high of $3.58. The firm has a market cap of $130.21 million, a PE ratio of -2.61 and a beta of 0.67. The business’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.70. The company has a quick ratio of 2.70, a current ratio of 3.09 and a debt-to-equity ratio of 1.18.

ObsEva (NASDAQ:OBSVGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). Equities research analysts anticipate that ObsEva will post -1.14 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in ObsEva in the first quarter valued at about $30,000. Banque Cantonale Vaudoise raised its position in ObsEva by 143.2% in the first quarter. Banque Cantonale Vaudoise now owns 28,868 shares of the company’s stock valued at $44,000 after purchasing an additional 17,000 shares during the period. Renaissance Technologies LLC purchased a new position in ObsEva in the fourth quarter valued at about $44,000. Dimensional Fund Advisors LP acquired a new stake in shares of ObsEva during the fourth quarter valued at about $62,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of ObsEva by 270.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 41,201 shares of the company’s stock valued at $82,000 after acquiring an additional 30,094 shares in the last quarter. 27.80% of the stock is currently owned by institutional investors.

ObsEva Company Profile (Get Rating)

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Read More

Get a free copy of the Zacks research report on ObsEva (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.